Search results
FDA advises Covid vaccine makers to target KP.2 for fall shots
NBC NEWS· 6 hours agoThe Food and Drug Administration said Thursday it had advised drugmakers to update the Covid ...
COVID summer guide: How to navigate symptoms, variants and vaccines this season
Yahoo Life· 7 hours agoWho should wait, and who should get vaccinated now? The CDC advises that everyone ages 5 and older...
KP.3 is the dominant COVID-19 variant in the US: Latest on test positivity, deaths, symptoms
USA Today· 8 hours agoCases of the latest COVID-19 variant, also known as KP.3, are on the rise in the United States....
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 1 day agoPfizer is competing against GSK's Arexvy, which hit the market about the same time in 2023. Moderna...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 7 hours agoNovavax will also receive tiered royalties on sales. Sanofi also made a $70 million investment in...
COVID Variant KP.3 Surges to Dominance—Here's What You Need to Know
Health via Yahoo News· 11 hours agoCases are “stable or uncertain” in 18 others and are likely declining in one—Oklahoma. Do Vaccines...
'Break their necks at the end of a rope': Alex Jones threatens people who 'lied to Trump'
The Raw Story· 2 days agoDuring a rant on his Tuesday broadcast, Jones initially said Trump's foes should be imprisoned...
Two shots in one? Moderna's COVID-19 and flu vaccine reports favorable results
USA Today· 4 days agoModerna said Monday that its combination vaccine against flu and COVID-19 drew a greater immune...
New COVID Vaccines Targeting JN.1 Will Arrive This Fall
Verywell Health via Yahoo News· 6 days agoVaccine manufacturers, including Pfizer, Moderna, and Novavax, have already been working on a JN.1...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 1 day agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin ...